Teneliximab (Synonyms: BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody) |
| カタログ番号GC20179 |
テネリキシマブ（BMS-224819）は、キメラ型モノクローナル抗体であり、CD40-CD40L相互作用を阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 299423-37-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion[1]
Review for Teneliximab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Teneliximab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *